Back to search

Article

XPA tumor variants lead to defects in NER that sensitize cells to cisplatin

2023-07-01

Abstract excerpt

Nucleotide excision repair (NER) neutralizes treatment with platinum (Pt)-based chemotherapy by removing Pt lesions from DNA. Previous study has identified that missense mutation or loss of either of the NER genes Excision Repair Cross Complementation Group 1 and 2 ( ERCC1 and ERCC2 ) leads to improved patient outcomes after treatment with Pt-based chemotherapies. Although most NER gene alterations found in pati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1b890ed2-e585-54cd-8d08-aae4a4aab364
DOI
10.1101/2023.06.29.547124
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
XPA tumor variants lead to defects in NER that sensitize cells to cisplatinDOI 10.1101/2023.06.29.547124
Select a neighboring publication to make it the new centre.